Compare Gilead Sciences, Inc. (GILD) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tapestry, Inc. — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Tapestry, Inc. trades at $116.24 (market cap $23.09B). The key difference: Gilead Sciences, Inc. is far larger — about 7.9× Tapestry, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Tapestry, Inc. for 70 Days on average.
| GILD | TPR | |
|---|---|---|
Market Cap | $182.40B | $23.09B |
Volume | 4,469,821 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $164.78 |
52-Week Low | $117.18 | $98.81 |
Typical Hold Time | 111 Days | 70 Days |
Enterprise Value | $205.46B | $25.89B |
Dividend Yield | 2.23% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Tapestry (TPR) trades at $115.82, up 2.14% today, with strong analyst support showing 73% buy ratings and a $174.64 consensus price target. The stock demonstrates robust profitability with 77.82% gross margins and 19.09% net income margin, though recent earnings show volatility with Q3 2026 results pending. Technical indicators signal bearish momentum with price near key support at $114, while fundamentals reveal mixed trends with revenue growth projected to $8B in 2026 but net income showing significant fluctuation from $183M in 2025 to projected $1.5B in 2026.
The investment case balances strong brand positioning and international growth potential against execution risks in the Kate Spade segment and tariff pressures. With the current price representing a 34% discount to analyst targets and institutional accumulation continuing, the stock offers upside potential for patient investors willing to navigate near-term volatility and margin expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
